Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
Objective: To evaluate the cost effectiveness of vedolizumab vs. infliximab in the treatment of anti-tumor necrosis factor-alpha (TNF-α)-naïve patients with moderate-to-severe active ulcerative colitis (UC) in China.Methods: The costs and effectiveness of vedolizumab and infliximab in the treatment...
Main Authors: | Ting Zhou, Yanan Sheng, Haijing Guan, Rui Meng, Zijing Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-08-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2021.704889/full |
Similar Items
-
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01) -
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01) -
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01) -
Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis
by: Raúl Vicente Olmedo-Martín, et al. -
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01)